Benitec FY2026 net loss $45.5M; BB-301 cohorts complete follow-up, FDA meeting held

Benitec Biopharma Inc.

FY2026 net loss attributable to shareholders was $45.5M ($0.98/share), vs $37.9M ($1.05/share) in FY2025.
Total expenses rose to $51.2M from $41.8M; R&D up to $23.4M, G&A up to $27.8M.
Cash and equivalents $180.0M at June 30, 2026.
All six Cohort 1 low-dose BB-301 patients completed 12-month follow-up; Cohort 2 fully enrolled, all treated safely.
Type C FDA meeting held in 3Q2026 on BB-301 pivotal design; minutes expected in October; pivotal trial init planned mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.